Skip to main content
. 2021 Jun 29;11:699781. doi: 10.3389/fonc.2021.699781

Figure 2.

Figure 2

Deterministic Sensitivity Analysis. The red solid line represents the willingness-to-pay threshold of $100,000 used this analysis. The black dotted line represents the incremental cost-effectiveness ratio (ICER) between alternatives under comparison. The top 10 most influential parameters of the ICERs are displayed. AEP indicated atezolizumab combined with etoposide and platinum; DEP, durvalumab combined with etoposide and platinum; QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio; AE, adverse event; PFS, progression-free survival; PS, progressed survival.